Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ARA 290 in no-option critical limb ischemia
NL-OMON28106Phase 2Suspended
- Sponsor
- Leiden University Medical Center
- Start
- Jan 2011
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cibinetide in chronic limb-threatening ischemia (CLTI), sponsored by Leiden University Medical Center. Primary endpoints: Safety and tolerability parameters, General safety measurements and 12 more. Started Jan 2011; status: suspended.
02
Drugs
cibinetide
03
Conditions
chronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on NL-OMON28106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28106.